Development of safe and effective treatments for aggressive neuroblastoma cancer

Neuroblastoma is a childhood cancer of abnormally developing nerve cells that affects mainly babies and young children. Although relatively unknown, the disease is one of the most common causes of cancer death in children under five.

What we’re doing

A gene called MYCN is linked to the growth and spread of aggressive neuroblastoma tumours. By developing new inhibitor drugs that are able to block this gene, researchers based at the world renowned Institute of Cancer Research aim to combat the most aggressive and dangerous form of this devastating disease. 

The potential impact

The team believe their research will produce tangible results that ultimately provide better treatments for children with neuroblastoma. Members of the team are optimistic that they can deliver new drugs for clinical use within the next five years.

Location

The Institute of Cancer Research, Royal Marsden Hospital, Surrey

Cost

£196,980 over 2 years

Map